Impact of tailored anti-P2Y12 therapies in acute coronary syndromes.
Acute coronary syndromes are a major disease burden and the prognosis has improved over the last decades due to improvement of medical and interventional treatments. Novel P2Y12-ADP-receptor antagonists have been introduced into clinical treatment offering more potent and rapid onset of action with the downside of increased bleeding risk. This special report will focus on interindividual variability of antiplatelet drugs in the setting of acute coronary syndromes and the current impact and potential future of point-of-care testing to personalize therapy aiming to improve prognosis in acute coronary syndrome patients.
University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany.
Fabian
F
Stimpfle
Tobias
T
Geisler
D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010979:Platelet Function Tests; D019095:Point-of-Care Systems; D057285:Precision Medicine; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D058925:Receptors, Purinergic P2Y12 / Q000187:drug effects*
D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12
acute coronary syndrome; clopidogrel; point-of-care; prasugrel; ticagrelor